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RESEARCH ARTICLE

A phase III trial of tirasemtiv as a potential treatment for
amyotrophic lateral sclerosis

JEREMY M. SHEFNER1,2, MERIT E. CUDKOWICZ3, ORLA HARDIMAN4,
BETTINA M. COCKROFT5, JACQUELINE H. LEE5, FADY I. MALIK5, LISA MENG5,
STACY A. RUDNICKI5, ANDREW A. WOLFF5 &, JINSY A. ANDREWS6 ON BEHALF
OF THE VITALITY-ALS STUDY GROUP
1

Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA, 2Department of Neurology,
University of Arizona, Phoenix, AZ, USA, 3Department of Neurology, Neurological Clinical Research Institute,
Massachusetts General Hospital, Boston, MA, USA, 4Academic Unit of Neurology, Trinity Biomedical Sciences
Institute, Trinity College, Dublin, Ireland, 5Cytokinetics, Inc, South San Francisco, CA, USA, and 6The
Neurological Institute, Columbia University, New York, NY, USA

Abstract
Objective: To assess the efficacy of tirasemtiv, a fast skeletal muscle troponin activator, vs. placebo in patients with amyotrophic lateral sclerosis. Methods: VITALITY-ALS (NCT02496767) was a multinational, double-blind, randomized, placebo-controlled clinical trial. Participants tolerating 2 weeks of open-label tirasemtiv (125 mg twice daily) were
randomized 3:2:2:2 to placebo or one of three target tirasemtiv dose levels, using an escalating dosage protocol lasting
28 days. The primary outcome measure was changed in slow vital capacity (SVC) at 24 weeks. Secondary endpoints
included a change in muscle strength and time to respiratory milestones of disease progression. Results: Of 744 participants, 565 tolerated open-label tirasemtiv and received randomized treatment. By 24 weeks, 23 (12.2%) placebo-treated
participants discontinued study treatment vs. 129 (34.2%) randomized to tirasemtiv. SVC declined by 14.4% (95% CI:
16.8, 11.9) in the placebo group and 13.4% (95% CI: 15.3, 11.6) in the tirasemtiv group (p ¼ 0.56). Secondary
endpoints did not show significant differences. However, participants who tolerated tirasemtiv at their randomized dose
showed a numeric trend toward a dose-related slowing of decline in SVC (p ¼ 0.11). Dizziness, fatigue, nausea, weight
loss, and insomnia occurred more frequently on tirasemtiv. Serious adverse events were similar across groups.
Conclusions: Tirasemtiv did not alter the decline of SVC or significantly impact secondary outcome measures. Poor tolerability of tirasemtiv may have contributed to this result. However, participants tolerating their intended dose exhibited a
trend toward treatment benefit on SVC, suggesting the underlying mechanism of action may still hold promise, as is
being tested with a different fast skeletal muscle troponin activator (NCT03160898).
KEYWORDS: Randomized clinical trial, amyotrophic lateral sclerosis, tirasemtiv

Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder causing progressive weakness
and death, on average 3–5 years after diagnosis
and most often as a result of respiratory failure (1–4).

Most therapeutic approaches to treating ALS
have targeted neurodegeneration, although skeletal
muscle is also a plausible target (5). Tirasemtiv, a
fast skeletal muscle troponin activator (FSTA),
increases skeletal muscle contractility by sensitizing
the sarcomere to calcium (6,7).
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A large, multinational, randomized, doubleblind, placebo-controlled, phase IIb clinical trial
(BENEFIT-ALS) (8) randomized 605 participants
with ALS who tolerated 1 week of open-label tirasemtiv 125 mg twice a day (BID). Participants
randomized to tirasemtiv underwent weekly dose
escalation to a maximum tolerated dose of 250 mg
BID in the 12-week, double-blind phase of the
study. No treatment effect was noted in the primary endpoint (change from baseline in ALS
Functional Rating Scale-Revised [ALSFRS-R]).
However, slow vital capacity (SVC) and muscle
strength declined significantly more slowly in tirasemtiv-treated participants (8). Tirasemtiv reduced
the slope of decline in SVC by 50% during the
12-week treatment phase (9). Dizziness was the
most commonly reported adverse event (AE) (8).
A phase III trial (VITALITY-ALS) was
designed to extend and confirm the findings of
BENEFIT-ALS. Double-blind treatment was
extended to 48 weeks, with the primary outcome,
change in SVC, evaluated at 24 weeks. To
improve tolerability, the open-label period was
extended to 2 weeks, and dose escalation occurred
every 2 weeks rather than weekly. Three target
dose levels were studied.
Methods
Participants
Adults with possible, probable, or definite ALS in
accordance with the revised El Escorial criteria
(10) were enrolled from 79 sites in 11 countries in
North America and Europe. Inclusion criteria
required an upright SVC 70% predicted for age,
height, and sex. No participants were taking edaravone during this study, and prior exposure to tirasemtiv was exclusionary.
Standard protocol approvals, registrations, and
patient consents
All participants in VITALITY-ALS provided written
informed consent, and institutional review board
approvals were received at all sites before enrollment. The study was conducted in accordance with
the Declaration of Helsinki. An independent data
and safety monitoring board monitored safety
throughout the study. This study was registered with
ClinicalTrials.gov (NCT02496767).
Study design
Following a screening period of up to 14 days, eligible participants were enrolled in the trial. The
study included an open-label phase; a 48-week,
double-blind, placebo-controlled phase; and then a
4-week, double-blind, placebo-controlled tirasemtiv
withdrawal phase intended to assess for a potential
rebound effect (none was observed, and not

further discussed here). Participants who successfully completed 2 weeks of treatment with openlabel tirasemtiv 125 mg BID were randomized
(using a centralized IWRS system) 3:2:2:2 to
matching placebo or one of three different target
daily dose levels of tirasemtiv (250, 375, or
500 mg) stratified by riluzole use vs. nonuse. It
was felt that patients who could not tolerate
125 mg BID as an initial dose would be unlikely to
complete the study, so we did not titrate to this
dose. All participants on riluzole took 50 mg daily
from their personal supply in the morning and a
blinded dose of riluzole in the evening in the same
manner as in BENEFIT-ALS. All participants
randomized to double-blind tirasemtiv continued at
250 mg/day (125 mg BID) for the first 2 weeks of
double-blind treatment. Participants randomized
to a target daily dosage of 375 mg (125 mg in the
morning and 250 mg in the evening) or 500 mg
(250 mg BID) of tirasemtiv had their dose adjusted
in 125-mg increments every 2 weeks until the target dose was reached or signs of intolerance
emerged, in which case the dose was not escalated
or was down-titrated to 250 mg daily of tirasemtiv
or matching placebo as necessary due to AEs. This
titration period was not included in the open-label
phase, as differential drop out would have rendered the 3 groups unequal.
The safety analysis set consisted of all participants who received any dose of study drug.
The full analysis set (FAS) included participants
who received at least one dose of study medication
during the randomized, double-blind, placebocontrolled phase and had at least one postrandomization efficacy assessment. There were a
total of six post randomization assessments
through 24 weeks. The per-protocol set (PPS)
consisted of all participants who completed
20 weeks of double-blind, placebo-controlled
treatment, had at least one post-randomization
efficacy assessment on double-blind study treatment, and had no major protocol violations.
Assessments
The last assessment obtained before the first dose
of the open-label phase was considered baseline.
The primary endpoint was change in percent predicted SVC from baseline to week 24 of the double-blind, placebo-controlled phase. Secondary
endpoints included muscle strength assessed by
hand-held dynamometry, the respiratory subscales
of the ALSFRS-R, and time to certain respiratory
milestones of disease progression, such as the initiation of assisted ventilation during the 48 weeks of
randomized, double-blinded treatment. Safety
assessments included physical examinations, clinical laboratory evaluations, vital signs, and monitoring of AEs and serious AEs (SAEs).

A phase III trial of tirasemtiv
Statistical methods

Results

The primary global null hypothesis was that no
treatment difference existed in the change from
baseline in percent predicted SVC at week 24
between participants in the FAS randomized to placebo and those randomized to tirasemtiv (pooled
three-target dosage levels) during placebo-controlled, double-blind treatment. The original protocol sample size estimation indicated that 360
participants were needed to complete the 24 weeks
of double-blind treatment to provide 90% power to
detect a treatment difference from placebo in percent predicted SVC change from baseline to the
end of the first 24-week phase of 6% (an 30%
change from placebo) for all tirasemtiv target dose
groups pooled using a common standard deviation
of 17% with a two-tailed alpha of 0.05. Dropout
rates of 16% at 24 weeks for placebo and 25% for
all tirasemtiv target dose groups combined were
assumed, necessitating 600 participants enrolled
in the study and 477 participants randomized to
placebo and the three different target dose levels of
tirasemtiv in an allocation ratio of 3:2:2:2 in the
double-blind, placebo-controlled treatment phase,
stratifying based on riluzole use. The final sample
size was slightly higher after adjusting for the aggregate blinded standard deviation and dropout rate
during the study. Subjects withdrawing from active
treatment were encouraged to attend all scheduled
study visits and complete assessments and, if unable
to attend, were contacted by phone on a monthly
basis to obtain vital status and respiratory status
through 48 weeks.
The primary analysis was performed using a
repeated-measures mixed model with restricted maximum likelihood method (PROC MIXED default;
R , Cary, NC). The model included terms for
SASV
treatment, baseline, pooled site, visit, and riluzole
use/nonuse as well as interaction terms for treatment-by-visit and baseline-by-visit with an unstructured covariance matrix. Multiple imputation by
randomized treatment dosage group was performed
for missing data prior to modeling. The repeatedmeasures mixed model was applied to other change
from baseline secondary endpoints. Cox regression
models were used to estimate the hazard ratios of
time to event endpoints between tirasemtiv and placebo, stratified by randomization strata.

Baseline characteristics

Data availability statement
In collaboration with the ALS association, this
study also included a biofluids collection at every
visit. All demographic and efficacy data will be
migrated to NeuroBANK, a database maintained
by the NEALS Biorepository. Biofluids and phenotypic data will be available through application to
the NEALS Biorepository Committee.
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Of 866 participants screened, 744 were enrolled
and 565 received randomized treatment (one
patient was randomized but did not receive the
treatment). After successfully completing the openlabel phase, 188 patients received at least one dose
of placebo and 377 received at least one dose of
tirasemtiv. Demographics at study entry (Table 1)
were similar to another recent phase III trials
(8,11–15). The majority of participants (74.5%
[554/744]) were taking riluzole at the start of the
study. Baseline characteristics between riluzole and
non-riluzole strata were similar.
Open-label phase
In the open-label phase of the study, 86.0% (640/
744) of participants experienced AEs, most commonly dizziness (48.5% [361/744]), fatigue
(27.4% [204/744]), and nausea (14.5% [108/
744]). Only 1.5% (11/744) of participants (4 not
taking and 7 taking riluzole) experienced SAEs;
23.7% (176/744) of participants discontinued from
the study during the open-label phase, with a similar discontinuation rate among participants taking
riluzole (26.7% [148/554]) and those not taking
riluzole (31.1% [59/190]) (Figure 1). AEs were
the most common reason for discontinuation, with
11.6% of participants (86/744) discontinuing
because of dizziness, 8.1% (60/744) because of
fatigue, and 4.2% (31/744) because of nausea.
Riluzole did not significantly affect the frequency
or type of AE resulting in discontinuation. The
baseline demographics and disease characteristics
of participants completing the open-label phase
and randomized into the double-blind, placebocontrolled phase were similar to those at the time
of entry into the open-label phase (Table 1).
Double-blind, placebo-controlled phase
Participant disposition is shown in Figure 1.
Overall, 183 participants were randomized to placebo; 165 (87.8%) completed 24 weeks of treatment, and 177 (94.1%) completed the week 24
visit. In contrast, 248 (65.8%) participants
randomized to tirasemtiv completed 24 weeks of
treatment and 311 (82.5%) completed the week
24 visit. There were 97 (77.0%), 60 (47.6%), and
39 (31.2%) patients who tolerated and achieved
their randomized target doses of 250 mg/day,
375 mg/day, and 500 mg/day at week 24, respectively. AEs were the most common reason for discontinuing therapy and were more common in
participants randomized to tirasemtiv. Termination
from treatment primarily occurred during the first
12 weeks and in relation to dose titration
(Figure 2); the frequency of study drug
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Table 1. Demographics and baseline disease characteristics.

Safety analysis set
Enrolled
(n 5 744)

Parameters
Age, y, mean (SD)
Age <65 y, n (%)
Male, n (%)
Riluzole user, n (%)
Weight, kg, mean (SD)
BMI, kg/m2, mean (SD)
Months from diagnosis, mean (SD)
Months from first symptom, mean (SD)
Bulbar onset, n (%)
ALSFRS-R total score, mean (SD)
ALSFRS-R respiratory domain score, mean (SD)
SVC (% predicted), mean (SD)

57.6
541
485
554
79.3
26.9
7.7
20.7
112
38.1
11.5
90.7

(10.3)
(72.7)
(65.2)
(74.5)
(15.4)
(4.2)
(5.8)
(13.8)
(15.1)
(5.1)
(0.9)
(15.7)

Full analysis
set
Placebo
(n 5 188)
55.9
143
123
141
80.7
27.3
8.1
21.5
31
38.3
11.6
90.7

(10.6)
(76.1)
(65.4)
(75.0)
(15.7)
(4.3)
(6.0)
(16.2)
(16.5)
(5.1)
(0.8)
(16.5)

All tirasemtiv
(n 5 373)
56.8
291
263
281
81.1
27.2
7.4
20.0
54
38.1
11.5
90.4

(10.0)
(78.0)
(70.5)
(75.3)
(14.8)
(4.1)
(5.6)
(12.9)
(14.5)
(5.3)
(0.9)
(15.3)

p value
0.29
0.61
0.30
0.84
0.71
0.81
0.19
0.39
0.53
0.68
0.23
0.85

ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; BMI: body mass index; SD: standard deviation; SVC:
slow vital capacity.

Safety Analysis Set

744
enrolled
179 lead-in
failures*
566
randomized*

188 received
placebo

377 received
tirasemtiv

23 (12.2%) stopped
treatment before week 24

129 (34.2%) stopped
treatment before week 24

• 8 AEs

• 100 AEs

• 3 deaths

• 5 deaths

• 5 progressive disease

• 10 progressive disease

• 5 other

• 8 other

• 1 withdrew consent

• 3 withdrew consent

• 0 protocol deviation

• 0 protocol deviation

• 1 physician judgment

• 1 physician judgment

• 0 lost to follow-up

• 2 lost to follow-up

165 (87.8%)
completed 24 weeks of
double-blind treatment

248 (65.8%)
completed 24 weeks of
double-blind treatment

33 (20.0%) stopped
treatment between
weeks 24 & 48

44 (17.7%) stopped
treatment between
weeks 24 & 48

• 5 AEs

• 9 AEs

• 7 deaths

• 7 deaths

• 8 progressive disease

• 21 progressive disease

• 4 other

• 3 other

• 3 withdrew consent

• 3 withdrew consent

• 1 protocol deviation

• 0 protocol deviation

• 3 physician judgment

• 0 physician judgment

• 2 lost to follow-up

• 1 lost to follow-up

132 (70.2%)
completed 48 weeks of
double-blind treatment

204 (54.1%)
completed 48 weeks of
double-blind treatment

Figure 1. Patient disposition. One patient was randomized but
did not receive study drug. AE: adverse event.

discontinuation was strongly related to the target
dosage level. Down-titrations also occurred early
but were not effective in deterring study drug discontinuation. Following 12 weeks of treatment

with the study drug, participants on placebo and
on tirasemtiv stopped treatment at similar rates
(Figure 2). AEs and SAEs are shown in Table 2
and Table 3, respectively; the AE profile was similar to the previously reported phase II trial. Rates
of SAEs and deaths were not different between
tirasemtiv- and placebo-treated groups. Seventeen
patients died during active treatment on placebo
[9.0%] as compared with 26 deaths during active
treatment on tirasemtiv [6.9%] after >1 year of
exposure to study medication.
At 24 weeks, there was no significant difference
in the decline in percent predicted SVC in the placebo-treated group compared with all tirasemtivtreated participants (14.4% for placebo, 13.4% for
all tirasemtiv; p ¼ 0.56). Decline in percent predicted SVC was 12.6% for the 250-mg target dose
group, 13.7% for the 375-mg target dose group,
and 13.9% for the 500-mg target dose group
(p ¼ 0.38, 0.76, and 0.84, respectively). There was
no significant difference between placebo and all
tirasemtiv-treated participants on the following secondary endpoints: ALSFRS-R respiratory domain
score change from baseline to week 48, slope of
Muscle Strength Mega-Score from baseline to
week 48, time to the first occurrence of a decline
from baseline in percent predicted SVC 20 percentage points or the onset of respiratory insufficiency or death to week 48, time to the first
occurrence of a decline in SVC 50% predicted
or the onset of respiratory insufficiency or death
over 48 weeks, change from baseline in the
ALSFRS-R total score to the end of week 48, and
time to first use of mechanical ventilator assistance
or death to week 48 (p ¼ 0.92, 0.75, 0.46, 0.76,
0.61, 0.65, respectively).
To assess whether a potential benefit of tirasemtiv was masked by poor tolerability, two separate analyses were performed on more restrictive
data sets. The PPS included participants who

A phase III trial of tirasemtiv
(A) 1.0
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Censored

Probability of staying on assigned dose

0.9

0.8

0.7

0.6

0.5

Placebo
250 mg
375 mg
500 mg
Log-rank test, placebo vs tirasemtiv: p<0.0001
Day 1

4

8

12

16

20

24

28

32

36

40

44

48

Weeks on double-blind treatment

(B) 1.0
Censored

0.9

0.8

0.7

0.6

0.5

Placebo
250 mg
375 mg
500 mg
Log-rank test, placebo vs tirasemtiv: p<0.0001
Day 1

4

8

12

16

20

24

28

32

36

40

44

48

154
91
76
68

147
90
74
66

145
88
73
65

135
85
71
61

92
64
47
39

Weeks on double-blind treatment
Placebo
250 mg
375 mg
500 mg

188
126
126
125

186
115
106
108

180
111
99
88

173
106
90
80

171
102
85
75

167
99
82
74

164
97
80
72

158
94
78
71

Figure 2. Probability of (A) staying on the assigned treatment dose and (B) staying on treatment.

completed 20 weeks of study medication and
contributed outcome measures at the 24-week
time point, when the primary outcome measure
was assessed. It eliminated participants who had
stopped study medication for >4 weeks and
includes no imputations for missing data.

However, participants who reduced their dose
were still included within their target dose group.
In this data set, the point estimate of effect was
greater than for the FAS; for the 250-mg target
dosage group in the PPS, percent predicted SVC
declined by 10.0 percentage points, compared
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Table 2. Most common TEAEs during the 48-week, double-blind, placebo-controlled phase.

Preferred term, n (%)

All
participants
(N 5 565)

Placebo
(n 5 188)

All
tirasemtiv
(n 5 377)

557
208
203
186
150
114
112
103
99
92
92
90
81
81
78
77
75
70
70
65
64

182 (96.8)
61 (32.4)
45 (23.9)
58 (30.9)
40 (21.3)
30 (16.0)
40 (21.3)
25 (13.3)
33 (17.6)
35 (18.6)
34 (18.1)
34 (18.1)
30 (16.0)
28 (14.9)
22 (11.7)
22 (11.7)
19 (10.1)
14 (7.4)
19 (10.1)
24 (12.8)
26 (13.8)

375
147
158
128
110
84
72
78
66
57
58
56
51
53
56
55
56
56
51
41
38

Patients with at least 1 TEAE
Fatigue
Dizziness
Muscular weakness
Weight decreased
Nausea
Constipation
Insomnia
Dysphagia
Dyspnea
Muscle spasms
Contusion
Nasopharyngitis
Headache
Asthenia
Depression
Decreased appetite
Somnolence
Anxiety
Skin abrasion
Posttraumatic pain

Difference
(%)

(99.5)
(39.0)
(41.9)
(34.0)
(29.2)
(22.3)
(19.1)
(20.7)
(17.5)
(15.1)
(15.4)
(14.9)
(13.5)
(14.1)
(14.9)
(14.6)
(14.9)
(14.9)
(13.5)
(10.9)
(10.1)

2.7
6.6
18
3.1
7.9
6.3
2.2
7.4
0.1
3.5
2.7
3.2
2.5
0.8
3.2
2.9
4.8
7.5
3.4
1.9
3.7

TEAE: treatment-emergent adverse event.

Table 3. Serious AEs occurring in >1% of participants during the 48-week double-blind phase.

Preferred term, n (%)

Placebo
(n 5 188)

Patients with serious AEs
Dysphagia
Respiratory failure
Decreased weight
Amyotrophic lateral sclerosis
Pneumonia
Pneumonia aspiration
Traumatic fracture

53
9
8
2
4
4
4
4

(28.2)
(4.79)
(4.26)
(1.06)
(2.13)
(2.13)
(2.13)
(2.13)

All tirasemtiv
(n 5 377)
92
21
17
10
6
4
2
2

(24.4)
(5.57)
(4.51)
(2.65)
(1.59)
(1.06)
(0.53)
(0.53)

Overall
(N 5 565)
145
30
25
12
10
8
6
6

(25.7)
(5.31)
(4.42)
(2.12)
(1.77)
(1.42)
(1.06)
(1.06)

AE: adverse event.

with 13.1 percentage points for the placebo group
(Table 4). This difference was not statistically significant (p ¼ 0.13), and there was an inverse doseresponse similar to the primary analysis, with participants randomized to higher dosage groups performing less well than the 250-mg target
dosage group.
A second analysis evaluated whether participants who tolerated their target dose level well
enough to stay at the target dose showed a greater
positive impact of tirasemtiv. Change in SVC was
evaluated as a function of average daily maintenance dosage from the end of week 8 for dose titration to the end of week 24. In this analysis, all
patients who remained on study drug through
24 weeks were included. The greatest estimate of
effect was noted in participants randomized to the
highest daily dosage (500 mg) who were able to
tolerate study drug at that dose (Figure 3).

Participants in this group showed a decline in percent predicted SVC of 9.7 percentage points compared with a drop of 14.2 percentage points in
placebo-treated participants (p ¼ 0.11). This difference represents a 32% slower decline in SVC for
those treated with tirasemtiv at a daily dosage of
500 mg compared with placebo treatment; if this
point estimate was a true effect of tirasemtiv in participants who tolerated this dose, such a difference
likely would be clinically important. Every 100 mg
of daily tirasemtiv was associated with a
0.19-percentage point (p ¼ 0.019) improvement in
change from baseline of percent predicted SVC
per month. This analysis suggested that there was
an expected dose response for those patients who
were able to tolerate tirasemtiv at their assigned
target dosage level, such that participants receiving
lower dosages experienced less of an effect than
those receiving higher dosages of tirasemtiv. No
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Table 4. Percent predicted SVC change from baseline to week 24 in PPS, mixed model for repeated measures.
Tirasemtiv
overall

Tirasemtiv
250 mg

Tirasemtiv
375 mg

Tirasemtiv
500 mg

239
10.9 (1.03)
2.2
(0.95, 5.31)
0.1715

91
10.0 (1.64)
3.1
(0.92, 7.10)
0.1310

79
10.7 (1.75)
2.4
(1.82, 6.58)
0.2656

69
12.4 (1.89)
0.8
(3.66, 5.16)
0.7387

Placebo
Patients in PPS, n
LS means (SE)
LS means from placebo (95% CI)

157
13.1 (1.26)

p value

CI: confidence interval; LS: least squares; PPS: per-protocol set; SE: standard error; SVC: slow vital capacity.

LS mean change from baseline in SVC (% predicted)

0

−5

−10

Placebo
187.5–312.5 mg/d
>312.5–437.5 mg/d
>437.5 mg/d

−15
0

4

8

12

16

24

20

Weeks
Number of patients on study medication
Placebo

188

186

169

187.5–312.5 mg/d

126

146

140

>312.5–437.5 mg/d

125

68

67

>437.5 mg/d

122

40

40

Change in SVC week 24
LS mean (percentage points)

Placebo

187.5–312.5
mg/d

>312.5–437.5
mg/d

>437.5
mg/d

−14.2

−11.7

−11.6

−9.7

2.6

2.7

4.6

0.160

0.247

0.107

LS mean difference from
placebo (percentage points)
P value

Figure 3. Change from baseline in percent predicted SVC in patients completing 24 weeks of treatment. Error bars represent standard
error of the mean. LS: least squares; SVC: slow vital capacity.

treatment effect was observed on ALSFRS-R and
hand-held dynamometry endpoints. When the
baseline characteristics of patients who remained
on double-blind treatment (whether at their target
doses or after down-titration) were compared to
those who did not, those who discontinued double-blind treatment were, on average, slightly
older, had lower vital capacities and ALSFRS-R
total scores (and were less likely to be scored as 4
on the dyspnea and orthopnea domains), were less

likely to be on riluzole, and were more likely to
use caffeine.
Discussion
In the primary analysis of the FAS, no significant
differences were seen in the primary outcome
measure or any secondary measures comparing all
tirasemtiv-treated participants with placebo-treated
participants. There appeared to be an inverse
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dose-response relationship with respect to the primary outcome measure. However, this is likely
spurious, as many higher-dosage participants had
been reduced to the lowest dose, and more had
also stopped study drug at higher dosages but
remained in the study providing outcome measure
data without receiving therapy.
Results demonstrated that tolerability was not
improved by the dosing strategies used in this
study, indicating that overall tolerability was dosedependent and not strongly improved by a slower
dose escalation. A slightly higher percentage of
participants withdrew during the open-label phase
as compared with BENEFIT-ALS. However, of
those who were randomized and continued into
the double-blind phase, approximately the same
percentage of participants stopped study drug by
12 weeks as compared with BENEFIT-ALS by
12 weeks. In both studies, study drug discontinuation occurred early, usually within 1 week of dose
escalation. Dose reductions also occurred early in
VITALITY-ALS but did not improve retention.
Participants who were randomized to higher dosages but were down-titrated to 125 mg BID were
much more likely to ultimately stop study drug
than those originally randomized to the same dosage. Participants on tirasemtiv also experienced
more AEs, most notably dizziness, fatigue, and
nausea. Importantly, however, there was no
increase in SAE rates in patients on active treatment and no indication of increased mortality.
Despite the impact of poor tolerability on the
results of this study, 2 analyses prespecified in the
protocol suggested a benefit in patients able to tolerate tirasemtiv. In the PPS, participants who were
randomized to the 250-mg target daily dose group
of tirasemtiv declined in SVC 24% more slowly
than those on placebo (Table 4). This change, if
true, would be clinically important; the fact that
the difference between active treatment and placebo was smaller than in BENEFIT-ALS may be
partially explained by the fact that the cohort as a
whole declined more slowly than expected (discussed below). The observation that the lower dosages were associated with larger treatment
differences was consistent with the inverse doseresponse relationship in tolerability among
randomized dosage groups. However, when participants were evaluated according to the maintenance dose from the end of week 8 to the end of
week 24, those who tolerated the highest average
daily dosage (500 mg of tirasemtiv daily), showed
an SVC decline that was 32% slower than those
on placebo in the FAS, with a positive doseresponse relationship. Overall, the poor tolerability
of tirasemtiv appears to have masked the potential
treatment benefit with regard to SVC. These
results suggest that the underlying mechanism of

action of tirasemtiv still has promise in patients
with ALS.
This study did not meet its primary endpoint.
Although there was a trend toward benefit in tirasemtiv-treated participants, it was not statistically
significant and not considered clinically meaningful. There are several reasons why a potential positive effect was obscured in this study. First, as
discussed above, tolerability was a significant issue,
with >50% more patients stopping study drug on
active treatment as compared with placebo. When
patients who tolerated tirasemtiv were evaluated
separately, much larger and potentially important
estimates of effect were seen. These effects did
not reach statistical significance at least in part
because of the small sample sizes in these groups.
Secondly, participants recruited to this study performed differently than other recent ALS cohorts,
at least with regard to SVC rate of change.
The decline in SVC was lower than expected.
Over 24 weeks, the decline in SVC was 14.2% or
0.080% per day in the placebo group for
VITALITY-ALS. For comparison, the rate of
decline for placebo-treated ALS patients in the
phase III trial of dexpramipexole was 0.088% per
day or 16.9% over 24 weeks and 0.090% per day
for the phase II trial of tirasemtiv. The slower progression rate in the current study may have contributed to the finding of no significant treatment
effect. However, as was noted in the phase 2 study
(BENEFIT ALS), SVC was the measure that
seemed to show the largest signal among all outcome measures, confirming that the choice in primary outcome measure was justified.
Thus, although this phase III study failed to
show a meaningful effect of tirasemtiv on SVC,
subanalyses suggest that tirasemtiv had a biological
effect on SVC, such that fast skeletal muscle
troponin activation remains worthy of further
study. A next-generation FSTA (reldesemtiv), lacking central nervous system effects and having the
potential to produce a larger pharmacodynamic
effect (16), has been reported to show promising
effects in spinal muscular atrophy (17) and is
being tested in a large phase II trial in ALS
patients (NCT03160898).
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